| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Özge Türkoğlu, Aygün Ertuğru. The Role of Cannabis in the Development of Psychosis. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 35. issue 3. 2024-09-03. PMID:39224996. |
additionally, evidence that dysfunctions in the endocannabinoid system play a role in the etiology of schizophrenia suggests that cannabis affects the disease process by worsening existing dysfunctions in this system. |
2024-09-03 |
2024-09-05 |
Not clear |
| Garrison J B Dyck, Zaid H Maayah, Dean T Eurich, Jason R B Dyc. Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144756. |
however, studies have shown that another major cannabinoid found in cannabis, cannabidiol (cbd), may be a potential alternative or adjunctive treatment for psychosis and schizophrenia. |
2024-08-15 |
2024-08-17 |
Not clear |
| Junjie Huang, Huan Huang, Moyin Liu, Wanlin Yang, Huiling Wan. Involvement of the TRPV1 receptor and the Endocannabinoid System in Schizophrenia. Brain research bulletin. 2024-06-09. PMID:38852650. |
involvement of the trpv1 receptor and the endocannabinoid system in schizophrenia. |
2024-06-09 |
2024-06-14 |
Not clear |
| Natalia Mansur Haddad, Leonardo Peroni De Jesus, Mauricio Serpa, Martinus Van De Bilt, Leda Talib, Alana Costa, Wagner Gattaz, Alexandre Andrade Loc. Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication. European archives of psychiatry and clinical neuroscience. 2024-03-19. PMID:38502208. |
endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication. |
2024-03-19 |
2024-03-23 |
Not clear |
| Natalia Mansur Haddad, Leonardo Peroni De Jesus, Mauricio Serpa, Martinus Van De Bilt, Leda Talib, Alana Costa, Wagner Gattaz, Alexandre Andrade Loc. Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication. European archives of psychiatry and clinical neuroscience. 2024-03-19. PMID:38502208. |
determining peripheral modulation of the endocannabinoid system (ecs) may be important for differentiating individuals with schizophrenia. |
2024-03-19 |
2024-03-23 |
Not clear |
| Brandon Richardson, Courtney Clarke, Jacqueline Blundell, Francis R Bambic. Therapeutic-like activity of cannabidiolic acid methyl ester in the MK-801 mouse model of schizophrenia: Role for cannabinoid CB1 and serotonin-1A receptors. The European journal of neuroscience. 2024-02-22. PMID:38385841. |
therapeutic-like activity of cannabidiolic acid methyl ester in the mk-801 mouse model of schizophrenia: role for cannabinoid cb1 and serotonin-1a receptors. |
2024-02-22 |
2024-02-24 |
mouse |
| Valéria de Almeida, Niele Dias Mendes, Giuliana S Zuccoli, Guilherme Reis-de-Oliveira, Glaucia M Almeida, Guilherme Gozzoli Podolsky-Gondim, Luciano Neder, Daniel Martins-de-Souza, Adriano Sebollel. NMDA glutamate receptor antagonist MK-801 induces proteome changes in adult human brain slices which are partially counteracted by haloperidol and clozapine. Journal of neurochemistry. 2024-02-09. PMID:38332572. |
next, using mass-spectrometry-based proteomics and systems biology in silico analyses, we found that mk-801 led to alterations in proteins related to several pathways previously associated with schizophrenia pathophysiology, including ephrin, opioid, melatonin, sirtuin signaling, interleukin 8, endocannabinoid, and synaptic vesicle cycle. |
2024-02-09 |
2024-02-11 |
human |
| Ana Canseco-Alba, Koichi Tabata, Momoki Yukihiko, Taharima Tabassum, Yasue Horiuchi, Tadao Arinami, Emmanuel S Onaivi, Hiroki Ishigur. Cannabinoid CB2 receptors and hypersensitivity to methamphetamine: Vulnerability to schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2023-12-22. PMID:38135096. |
cannabinoid cb2 receptors and hypersensitivity to methamphetamine: vulnerability to schizophrenia. |
2023-12-22 |
2023-12-25 |
mouse |
| Helena K Kim, Vanessa F Gonçalves, Muhammad I Husain, Daniel J Müller, Benoit H Mulsant, Gwyneth Zai, Stefan Kloibe. Cross-disorder GWAS meta-analysis of endocannabinoid DNA variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia. Psychiatry research. vol 330. 2023-11-04. PMID:37924773. |
cross-disorder gwas meta-analysis of endocannabinoid dna variations in major depressive disorder, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, and schizophrenia. |
2023-11-04 |
2023-11-08 |
Not clear |
| Pukar Khanal, Vishal S Patil, B M Patil, Kunal Bhattacharya, Amit Kumar Shrivastava, Raushan K Chaudhary, Lokjan Singh, Prarambh Sr Dwivedi, Darasaguppe R Harish, Subarna Ro. The marijuana-schizophrenia multifaceted nexus: Connections and conundrums towards neurophysiology. Computational biology and chemistry. vol 107. 2023-09-20. PMID:37729848. |
it was found that delta-9-tetrahydrocannabinol may have an impact on the brain's endocannabinoid system and may trigger the schizophrenia progression in vulnerable people. |
2023-09-20 |
2023-10-07 |
Not clear |
| Stav Bloch Priel, Assif Yitzhaky, David Gurwitz, Libi Hertzber. Cannabinoid receptor gene CNR1 is downregulated in subcortical brain samples and upregulated in blood samples of individuals with schizophrenia: A participant data systematic meta-analysis. The European journal of neuroscience. 2023-08-23. PMID:37611908. |
cannabis use leads to symptom exacerbation in schizophrenia patients, and endocannabinoid ligands have been studied as tentative schizophrenia therapeutics. |
2023-08-23 |
2023-09-07 |
human |
| Shinnyi Chou, Kenneth N Fish, David A Lewis, Robert A Swee. Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: A pilot study. Neurobiology of disease. 2023-08-16. PMID:37586566. |
terminal type-specific cannabinoid cb1 receptor alterations in patients with schizophrenia: a pilot study. |
2023-08-16 |
2023-09-07 |
human |
| Shinnyi Chou, Kenneth N Fish, David A Lewis, Robert A Swee. Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: a pilot study. bioRxiv : the preprint server for biology. 2023-04-24. PMID:37090672. |
terminal type-specific cannabinoid cb1 receptor alterations in patients with schizophrenia: a pilot study. |
2023-04-24 |
2023-08-14 |
human |
| Martina Di Bartolomeo, Tibor Stark, Serena Di Martino, Fabio Arturo Iannotti, Jana Ruda-Kucerova, Giovanni Luca Romano, Martin Kuchar, Samuele Laudani, Petr Palivec, Fabiana Piscitelli, Carsten T Wotjak, Claudio Bucolo, Filippo Drago, Vincenzo Di Marzo, Claudio D'Addario, Vincenzo Mical. The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology. International journal of molecular sciences. vol 24. issue 4. 2023-02-25. PMID:36835313. |
adolescent exposure to cannabinoids as a postnatal environmental insult may increase the risk of psychosis in subjects exposed to perinatal insult, as suggested by the two-hit hypothesis of schizophrenia. |
2023-02-25 |
2023-08-14 |
human |
| Błażej Misiak, Tomasz Bielawski, Jerzy Samochowiec, Agnieszka Samochowiec, Mariusz G Fleszar, Paulina Fortuna, Bogna Kosyk, Dorota Frydeck. Activation of the endocannabinoid system in schizophrenia: A compensatory mechanism of subclinical inflammation? Schizophrenia research. vol 252. 2023-01-11. PMID:36628871. |
activation of the endocannabinoid system in schizophrenia: a compensatory mechanism of subclinical inflammation? |
2023-01-11 |
2023-08-14 |
Not clear |
| Marta Barrera-Conde, Emma Veza-Estévez, Maria Gomis-Gonzalez, Jordi Garcia-Quintana, Amira Trabsa, Laura Martínez-Sadurní, Mitona Pujades, Víctor Perez, Rafael de la Torre, Daniel Bergé, Patricia Robled. Role of cyclin-dependent kinase 5 in psychosis and the modulatory effects of cannabinoids. Neurobiology of disease. vol 176. 2022-12-09. PMID:36473591. |
its expression is altered in treated schizophrenia patients, and cannabinoids modulate cdk5 levels in the brain of rodents. |
2022-12-09 |
2023-08-14 |
mouse |
| Gabriela Visini, Samara Brown, Katrina Weston-Green, Cynthia Shannon Weickert, Rose Chesworth, Tim Kar. The effects of preventative cannabidiol in a male Frontiers in cellular neuroscience. vol 16. 2022-11-21. PMID:36406747. |
the effects of preventative cannabidiol in a male cannabidiol (cbd) is a non-intoxicating cannabinoid with antipsychotic-like properties, however it's potential to prevent schizophrenia development has not been thoroughly investigated. |
2022-11-21 |
2023-08-14 |
Not clear |
| Inés Ibarra-Lecue, Paula Unzueta-Larrinaga, Rocío Barrena-Barbadillo, Aitor Villate, Igor Horrillo, Begoña Mendivil, Miguel A Landabaso, J Javier Meana, Nestor Etxebarria, Luis F Callado, Leyre Urigüe. Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients. Addiction biology. vol 27. issue 6. 2022-10-27. PMID:36301212. |
likewise, endocannabinoid system dysregulation has been suggested in schizophrenia. |
2022-10-27 |
2023-08-14 |
human |
| Rachel Little, Dale D'Mell. A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis. Innovations in clinical neuroscience. vol 19. issue 7-9. 2022-10-07. PMID:36204167. |
a cannabinoid hypothesis of schizophrenia: pathways to psychosis. |
2022-10-07 |
2023-08-14 |
Not clear |
| Giuliana S Zuccoli, Caroline Brandão-Teles, Gabriela Maciel Vieira, Felipe V Gomes, Fernanda Crunfl. Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia. Advances in experimental medicine and biology. vol 1400. 2022-08-05. PMID:35930228. |
molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia. |
2022-08-05 |
2023-08-14 |
Not clear |